Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus

This publication has 19 references indexed in Scilit:

• Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450‐Inducing Medications¹
  The Journal of Clinical Pharmacology, 2007
• Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Everolimus drug interactions: application of a classification system for clinical decision making
  Biopharmaceutics & Drug Disposition, 2006
• Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
  Journal of Clinical Oncology, 2004
• Determination of Volume of Distribution at Steady State with Complete Consideration of the Kinetics of Protein and Tissue Binding in Linear Pharmacokinetics
  Journal of Pharmaceutical Sciences, 2004
• mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E
  Molecular and Cellular Biology, 2004
• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
  Annals of Oncology, 2003
• Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin
  Molecular and Cellular Biology, 2002
• TOR, a Central Controller of Cell Growth
  Cell, 2000
• Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition
  Clinical Pharmacokinetics, 2000